- Home
- MAS vs CNTX Comparison
MAS vs CNTX Comparison
Compare MAS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- CNTX
- Stock Information
- Founded
- MAS 1929
- CNTX 2015
- Country
- MAS United States
- CNTX United States
- Employees
- MAS N/A
- CNTX N/A
- Industry
- MAS Industrial Specialties
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MAS Industrials
- CNTX Health Care
- Exchange
- MAS Nasdaq
- CNTX Nasdaq
- Market Cap
- MAS N/A
- CNTX 76.5M
- IPO Year
- MAS N/A
- CNTX 2021
- Fundamental
- Price
- MAS $73.29
- CNTX $1.02
- Analyst Decision
- MAS Buy
- CNTX Strong Buy
- Analyst Count
- MAS 13
- CNTX 5
- Target Price
- MAS $87.38
- CNTX $6.70
- AVG Volume (30 Days)
- MAS 1.3M
- CNTX 1.1M
- Earning Date
- MAS 02-06-2025
- CNTX 11-06-2024
- Dividend Yield
- MAS 1.61%
- CNTX N/A
- EPS Growth
- MAS 2.74
- CNTX N/A
- EPS
- MAS 3.76
- CNTX N/A
- Revenue
- MAS $7,882,000,000.00
- CNTX N/A
- Revenue This Year
- MAS N/A
- CNTX N/A
- Revenue Next Year
- MAS $0.93
- CNTX N/A
- P/E Ratio
- MAS $19.20
- CNTX N/A
- Revenue Growth
- MAS N/A
- CNTX N/A
- 52 Week Low
- MAS $63.81
- CNTX $0.89
- 52 Week High
- MAS $86.70
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- MAS 36.65
- CNTX 37.22
- Support Level
- MAS $71.02
- CNTX $0.98
- Resistance Level
- MAS $72.61
- CNTX $1.29
- Average True Range (ATR)
- MAS 1.25
- CNTX 0.15
- MACD
- MAS 0.05
- CNTX 0.02
- Stochastic Oscillator
- MAS 36.72
- CNTX 20.75
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.